Reply to Dr Bell

Journal of Perinatology

Volumn 28, Issue 5, 2008, Pages 383-384

  Gordon, P V ^a   Swanson, J R ^b   Attridge, J T ^b   Clark, R ^c  

^a Ochsner Health Systems   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c Pediatrix Medical Group Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

CLINICAL TRIAL; ENTEROPATHY; EXTREMELY LOW BIRTH WEIGHT; HUMAN; INTESTINE PERFORATION; LETTER; NECROTIZING ENTEROCOLITIS; NEONATAL INTESTINAL DISEASE; NEWBORN; NEWBORN DISEASE; NEWBORN MORBIDITY; NEWBORN MORTALITY; PRACTICE GUIDELINE; RISK FACTOR;

EID: 43049118969     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2008.26     Document Type: Letter

References (5)

1. Bell MJ. Letter to the editor. J Perintol 2008 (in press).
2. Deshpande G, Rao S, Patole S. Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birthweight: A systematic review of randomised controlled trials. Lancet 2007; 369: 1578-1580.
3. Moss RI, Dimmitt RA, Barnhart DC, Sylvester KG, Brown RI, Powell DM et al. Laparotomy versus peritoneal drainage for necrotizing enterocolitis and perforation. N Engl J Med 2006; 354: 2225-2234.
4. Hintz SR, Kendrick DE, Stoll BJ, Vohr BR, Fanaroff AA, Donovan EF et al. Neurodevelopmental and groth outcomes of extremely low birth weight infants after necrotizing enterocolitis. Pediatrics 2005; 115: 696-703.
5. Gordon PV, Swanson JR Attridge JT, Clark R. Emerging trends in acquired neonatal intestinal disease: Is it time to abandon Bell's criteria? J Perinatol 2007; 27: 661-671.